Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HROW 
Harrow Health Inc (HROW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: HROW (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 54.89% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 934.50M USD | Price to earnings Ratio - | 1Y Target Price 57.88 |
Price to earnings Ratio - | 1Y Target Price 57.88 | ||
Volume (30-day avg) 515203 | Beta 0.69 | 52 Weeks Range 9.86 - 59.23 | Updated Date 03/30/2025 |
52 Weeks Range 9.86 - 59.23 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate 0.13 | Actual 0.4 |
Profitability
Profit Margin -8.76% | Operating Margin (TTM) 19.68% |
Management Effectiveness
Return on Assets (TTM) 1.62% | Return on Equity (TTM) -25.02% |
Valuation
Trailing PE - | Forward PE 125 | Enterprise Value 1116076821 | Price to Sales(TTM) 4.68 |
Enterprise Value 1116076821 | Price to Sales(TTM) 4.68 | ||
Enterprise Value to Revenue 5.59 | Enterprise Value to EBITDA 55.8 | Shares Outstanding 35654200 | Shares Floating 26959901 |
Shares Outstanding 35654200 | Shares Floating 26959901 | ||
Percent Insiders 13.47 | Percent Institutions 59.04 |
Analyst Ratings
Rating 5 | Target Price 59.85 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Harrow Health Inc
Company Overview
History and Background
Harrow Health, Inc., founded in 2014, is a pharmaceutical company focused on acquiring, developing, and commercializing innovative pharmaceutical products. It was initially known as Imprimis Pharmaceuticals before rebranding to Harrow Health to reflect its broader strategic focus on the ophthalmic pharmaceutical market. It has grown through acquisitions and organic development of new products.
Core Business Areas
- Ophthalmology: Harrow focuses on developing and commercializing ophthalmic pharmaceutical products, including prescription medications and compounded formulations for eye care professionals and their patients.
- Drug Compounding: Harrow is also involved in drug compounding, creating customized medications tailored to individual patient needs. This is primarily through its subsidiaries.
Leadership and Structure
Mark L. Baum serves as the Chief Executive Officer. The company has a board of directors overseeing corporate governance. The organizational structure is based on functional departments such as research and development, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- IHEEZO: IHEEZO (chloroprocaine ophthalmic gel) 3% is a topical anesthetic indicated for ocular surface anesthesia. Harrow Health acquired the US commercial rights. Market share data is still evolving as it's a relatively new product but aims to compete with existing anesthetics used during eye procedures. Competitors include Alcon with products like Alcaine and Bausch + Lomb
- FORTISITE: Fortisite is a compounded version of Vancomycin for endophthalmitis. Market share data is not readily available given the nature of compounding pharmacies. Competitors are traditional pharmaceutical companies marketing anti-infective agents.
- MAZERA: Mazera, a compounded product, is another specialized ophthalmic medication offered through Harrow's compounding pharmacy network. Market share data not readily available. Competitors are traditional pharmaceutical companies marketing anti-inflammatory and glaucoma medication.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The ophthalmic segment is driven by aging populations, increasing prevalence of eye diseases, and technological advancements in treatment options.
Positioning
Harrow Health focuses on niche markets within the pharmaceutical space, specifically ophthalmic pharmaceuticals. Its strategy involves acquiring and developing specialized products and offering compounded medications to cater to individual patient needs. Its competitive advantage lies in its specialized focus and ability to innovate in niche segments.
Total Addressable Market (TAM)
The global ophthalmic pharmaceutical market is estimated to be over $40 billion. Harrow is positioned to capture a portion of this TAM through strategic acquisitions, new product development, and customized compounding services.
Upturn SWOT Analysis
Strengths
- Specialized focus on ophthalmic pharmaceuticals
- Strong compounding capabilities
- Experienced management team
- Proprietary and differentiated products
- Growing revenue
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on acquisitions for growth
- Compounding segment may face regulatory scrutiny
- Relatively small market capitalization
Opportunities
- Further acquisitions of complementary pharmaceutical products
- Expansion of international markets
- Development of innovative ophthalmic therapies
- Increasing demand for personalized medications
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes impacting the compounding industry
- Product liability claims
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- PZOO
Competitive Landscape
Harrow Health competes with larger pharmaceutical companies in the ophthalmic market. Its competitive advantage lies in its specialized focus, innovative products, and compounding capabilities. However, it faces challenges related to scale and financial resources.
Major Acquisitions
US commercial rights for IHEEZO
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: Expanding Harrow's product portfolio in the ocular anesthesia space.
Growth Trajectory and Initiatives
Historical Growth: Harrow has grown primarily through acquisitions of ophthalmic products and the expansion of its compounding business.
Future Projections: Analysts project continued growth in revenue driven by sales of IHEEZO and other ophthalmic products, as well as expansion of the compounding segment.
Recent Initiatives: Recent initiatives include the launch of IHEEZO, strategic acquisitions of ophthalmic assets, and expansion of the compounding pharmacy network.
Summary
Harrow Health is a pharmaceutical company with a specialized focus on ophthalmic products. It has grown through strategic acquisitions and expansion of its compounding business. Strengths include specialized focus and growing revenue streams; weaknesses relate to size and reliance on acquisitions. Continued growth will depend on successful product launches, prudent acquisitions, and managing competitive pressures.
Similar Companies
- ALC
- VRX
- PZOO
Sources and Disclaimers
Data Sources:
- Company website
- Public filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are based on available data and may not be precise. Investment decisions should be made based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harrow Health Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2007-09-28 | CEO & Chairman of the Board Mr. Mark L. Baum J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.harrow.com |
Full time employees - | Website https://www.harrow.com | ||
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.